Jane Street Group LLC Buys 3,342 Shares of biote Corp. (NASDAQ:BTMD)

Jane Street Group LLC grew its stake in biote Corp. (NASDAQ:BTMD) by 24.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,873 shares of the company’s stock after acquiring an additional 3,342 shares during the quarter. Jane Street Group LLC’s holdings in biote were worth $94,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BTMD. Bank of New York Mellon Corp grew its holdings in biote by 59.0% during the second quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock valued at $705,000 after purchasing an additional 34,999 shares during the period. Rhumbline Advisers boosted its position in shares of biote by 104.2% during the second quarter. Rhumbline Advisers now owns 28,225 shares of the company’s stock worth $211,000 after purchasing an additional 14,404 shares in the last quarter. WINTON GROUP Ltd grew its holdings in shares of biote by 7.0% in the 2nd quarter. WINTON GROUP Ltd now owns 47,725 shares of the company’s stock valued at $357,000 after buying an additional 3,124 shares during the period. Dimensional Fund Advisors LP increased its position in shares of biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after buying an additional 600,956 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in biote by 251.8% during the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock worth $1,442,000 after buying an additional 138,200 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Craig Hallum assumed coverage on biote in a research note on Monday, December 16th. They issued a “buy” rating and a $12.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $9.11.

biote Stock Up 2.3 %

Shares of BTMD stock opened at $5.67 on Wednesday. The company has a market capitalization of $308.09 million, a price-to-earnings ratio of 21.81 and a beta of 1.08. biote Corp. has a 12-month low of $3.65 and a 12-month high of $8.44. The firm has a fifty day moving average of $6.16 and a 200-day moving average of $6.23.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.